Regulatory News Item

RNS Number : 4752X
Smiths Group PLC
21 February 2017


News Release

London, 21 February 2017

For immediate release



Smiths Group publishes Final Terms of Notes

Smiths Group plc (the "Company") has published final terms dated 21 February 2017 ("Final Terms") relating to the €650,000,000 2.00% notes due 2027, issued by the Company and guaranteed by Smiths Group International Holdings Limited under the Company's €2,500,000,000 Euro Medium Term Note Programme (the "EMTN Programme").

The Final Terms must be read in conjunction with the base prospectus for the EMTN Programme dated 17 October 2016 (the "Prospectus").

To view the Final Terms, please paste the following URL into the address bar of your browser:

The Final Terms have been submitted to the National Storage Mechanism and will shortly be available for inspection at: 





Contact details


Investor enquiries

Andrew Lappin, Smiths Group

+44 (0)20 7004 1657

+44 (0)78 5461 1966


Marion Le Bot, Smiths Group

+44 (0)20 7004 1672

+44 (0)75 8315 4386


Media enquiries

Andrew Lorenz, FTI Consulting

+44 (0)203 727 1323

+44 (0)777 564 1807



Smiths is a global technology company listed on the London Stock Exchange (SMIN) and operates a sponsored level one ADR programme (SMGZY). A world leader in the practical application of technologies, Smiths Group delivers products and services for the threat & contraband detection, medical devices, energy and communications markets worldwide. Our products and services make the world safer, healthier and more productive. Smiths Group employs 22,000 people in over 50 countries. For more information visit



Disclaimer - intended addressees

Please note that the information contained in the Final Terms (when read together with the information in the Prospectus) may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms and the Prospectus is not addressed. Prior to relying on the information contained in the Final Terms and the Prospectus, you must ascertain from the Prospectus whether or not you are one of the intended addressees of the information contained therein.

In particular, neither the Final Terms nor the Prospectus constitute an offer of securities for sale in the United States. Neither the Final Terms nor the Prospectus nor this announcement is intended for distribution in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements. Subject to certain exceptions, the securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America, as such terms are defined in Regulation S under the Securities Act. There will be no public offering of the securities in the United States.

Your right to access this service is conditional upon complying with the above requirement.



This information is provided by RNS
The company news service from the London Stock Exchange